Skip to main content
An official website of the European UnionAn official EU website
European Commission logo
English English
CORDIS - EU research results
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Development and evaluation of Radical Oxygen Species (ROS)-responsive drug delivery systems to prevent and cure inflammatory and hypoxic diseases.

Project description

Smart drugs for treating inflammatory conditions

Reactive oxygen species (ROS) are highly reactive molecules containing oxygen and emerge as natural byproducts of the normal metabolism of oxygen. Although ROS are implicated in cell signaling and homeostasis, they can damage DNA and other macromolecules, leading to cellular dysfunction and oxidative stress. Funded by the Marie Skłodowska-Curie Actions programme, the ROSCURE-O2 project proposes a way to explore endogenous ROS levels for the delivery of anti-inflammatory drugs. Researchers will develop a smart drug delivery system based on nanoparticles that scavenge ROS levels in inflamed tissues. This system offers an innovative approach for treating inflammatory conditions like radiation-induced skin injuries.

Objective

The evolving landscape of medical research demands innovative breakthroughs to enhance disease treatments. Smart drug delivery systems (DDS) are at the forefront of these innovations, offering precise drug release while combatting oxidative stress and harmful species. ROSCURE-O2 (Radical Oxygen Species (ROS)-responsive drug delivery systems to prevent and cure inflammatory and hypoxic diseases), is a pioneering proposal focusing on engineering ROS-responsive DDS with anti-inflammatory and anti-hypoxia properties.Inflammation profoundly affects global health, contributing to various skin and wound conditions, including radiation-induced skin injuries (RISI). RISI arises from healthy cells' exposure to ionizing radiation used in cancer radiotherapy, leading to issues ranging from mild skin reactions to severe burns, ulcers, infections, and necrosis, impacting the quality of life for over 95% of radiotherapy patients.

ROSCURE-O2 aims to develop innovative treatments for inflammatory conditions by targeting ROS and hypoxia precisely. The hypothesis posits that multifunctional DDS can (1) scavenge ROS, (2) selectively release anti-inflammatory drugs, and (3) deliver oxygen in ROS-rich environments, thus preventing and curing inflammatory diseases. This triple therapeutic approach seeks to overcome the limitations of conventional treatments.

Within ROSCURE-O2 the development of a Smart DDS platform that can synergistically address ROS and hypoxia. This involves polymeric DDS with ROS-responsive properties, provided by sulfur-based chemistries and/or antioxidant crosslinkers and the incorporation of oxygen-releasing and ROS-scavenging nanoparticles, like Cerium Oxide. These nanoparticles can be combined with anti-inflammatory active pharmaceutical ingredients to increase treatment efficacy and reduce costs. ROSCURE-O2's outcomes have the potential to advance our understanding of ROS-responsive drug delivery and tissue regeneration through oxygen delivery.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.

You need to log in or register to use this function

Coordinator

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Net EU contribution
€ 165 312,96
Address
CALLE SERRANO 117
28006 Madrid
Spain

See on map

Region
Comunidad de Madrid Comunidad de Madrid Madrid
Activity type
Research Organisations
Links
Total cost
No data